Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H11Cl2N3O5S |
| Molecular Weight | 368.193 |
| Optical Activity | NONE |
| Additional Stereochemistry | Yes |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | NON-INVERSION AT THE NITROGEN R STEREOCHEMISTRY |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)N(CCO)C1=C2NC(=O)C(=O)NC2=CC(Cl)=C1Cl
InChI
InChIKey=BGJHUMNCODFLCH-UHFFFAOYSA-N
InChI=1S/C11H11Cl2N3O5S/c1-22(20,21)16(2-3-17)9-7(13)5(12)4-6-8(9)15-11(19)10(18)14-6/h4,17H,2-3H2,1H3,(H,14,18)(H,15,19)
| Molecular Formula | C11H11Cl2N3O5S |
| Molecular Weight | 368.193 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:24:12 GMT 2025
by
admin
on
Tue Apr 01 17:24:12 GMT 2025
|
| Record UNII |
9QU5W0O2DX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
178908-09-3
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY | |||
|
DTXSID30873385
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY | |||
|
9QU5W0O2DX
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY | |||
|
UK-240455
Created by
admin on Tue Apr 01 17:24:12 GMT 2025 , Edited by admin on Tue Apr 01 17:24:12 GMT 2025
|
PRIMARY | HY-19391 CAS:178908-09-3, (Synonyms UK240455, UK 240455) 178908-09-3 Technical Data |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Neuroprotectant, Mechanism of Action: NMDA receptor antagonist, Highest Development Phase: Discontinued for Stroke
|
||
|
ACTIVE MOIETY |
Pfizer is developing the atropoisomeric quinoxalinediones, UK-315716 and UK-240255, from a series of NMDA/glycine antagonists for the potential treatment of stroke. Both are compounds are undergoing clinical trials. UK-315716 has improved aqueous solubility and in vivo efficacy over UK-240455, and a lower projected clinical dose of 200 mg compared to 500 mg with UK-240455.
|
